{"filings":[{"id":2474996,"accession_number":"0001935979-26-000072","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2026-08-26T10:38:55+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Biohaven licenses opakalim/Kv7 platform to SK Biopharmaceuticals for up to $795M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["SK Biopharmaceuticals licenses Biohaven's Kv7 platform led by opakalim, a Phase 2/3 selective Kv7.2/7.3 activator for focal epilepsy.","Biohaven receives $400M upfront ($350M at close, $50M in 2027) plus up to $150M development and regulatory milestones.","Tiered royalties on U.S. opakalim net sales range from mid-teens to low twenties; mid-single-digit on ex-U.S. net sales.","SKBP assumes up to $245M Knopp obligations: $185M on U.S./EMA approval of opakalim and up to $60M for future Kv7 programs.","Closing subject to antitrust clearance (HSR); RISE3 topline results expected in 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2162876,"accession_number":"0001935979-26-000067","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2026-08-10T20:22:45+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biohaven Q2 net loss narrows to $137.3M; advances Graves, epilepsy, oncology pipeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $137.3M ($0.91/share) vs $198.1M ($1.94/share) in Q2 2025; non-GAAP loss $118.1M ($0.78/share).","Cash, equivalents, marketable securities and restricted cash totaled ~$270.5M as of June 30, 2026.","BHV-1300 Phase 3 in Graves' initiated; Phase 1b showed >80% mean reduction of pathogenic TSHR-IgG1 by week 12.","Opakalim RISE3 topline expected 2H 2026; IGE study showed median time to second seizure 141 vs 47 days placebo.","New clinical supply agreement with Regeneron to evaluate BHV-1530 ADC in combination with Libtayo."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2133197,"accession_number":"0001935979-26-000060","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2026-08-07T20:10:34+00:00","items":["5.02","9.01"],"status":"ready","headline":"Biohaven appoints John Yetimoglu to board, effective Aug 6, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Yetimoglu appointed to Biohaven board effective Aug 6, 2026; term expires at 2027 annual meeting.","Granted options with aggregate grant date fair value of $713,875; vest 25% on grant, 25% annually over 3 years.","Receives $57,000 annual retainer for director and committee service; joins Nominating and Governance Committee.","No family relationships or reportable transactions with company per Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1555676,"accession_number":"0001935979-26-000053","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2026-07-09T21:11:27+00:00","items":["5.02","9.01"],"status":"ready","headline":"Biohaven CSO Bruce Car retires to part-time Chief Innovation Officer; Pirman promoted to EVP Discovery","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bruce Car retires as CSO, becomes part-time Chief Innovation Officer effective July 13, 2026, focusing on external collaborations including Bexorg.","David Pirman promoted to EVP and Head of Discovery, leading internal drug-discovery organization.","Warren Volles, General Counsel and Chief Legal Officer, designated an executive officer.","Dr. Car's salary reduced by 50% to reflect part-time work schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":697959,"accession_number":"0001935979-26-000048","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2026-05-27T21:13:33+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biohaven reports positive clinical data for opakalim in epilepsy and BHV-1300/BHV-1400 in autoimmune diseases at R&D Day","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Opakalim 75 mg prolonged median time to second seizure to 141 days vs 47 days for placebo in idiopathic generalized epilepsy trial.","54% of focal epilepsy patients on opakalim achieved ≥50% seizure reduction over six months in open-label extension.","BHV-1300 reduced pathogenic TSHR-IgG1 >80% by week 12 and normalized thyroid hormones within weeks in Graves' disease patients.","BHV-1400 reduced Gd-IgA1 >60% within hours and 70% within one month in IgA nephropathy, with early eGFR and UPCR improvements.","Both degrader programs showed well-tolerated safety profiles with no serious adverse events; pivotal Phase 3 trials expected to initiate mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96804,"accession_number":"0001628280-26-030579","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biohaven establishes $350M at-the-market equity offering via amended agreement with J.P. Morgan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 2 to Equity Distribution Agreement allows up to $350M in common share sales.","J.P. Morgan Securities acts as manager for ATM program on NYSE at prevailing market prices.","New shelf registration (File No. 333-295531) and prospectus supplement filed May 4, 2026.","Proceeds for general corporate purposes; timing and amount depend on market conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96803,"accession_number":"0001935979-26-000044","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biohaven Q1 net loss $130.5M; pivotal epilepsy & obesity data due 2H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $130.5M ($0.88/sh) vs $221.7M ($2.17/sh) in Q1 2025; non-GAAP adjusted loss $102.2M ($0.69/sh).","Cash, equivalents & securities totaled $351.8M at March 31, 2026.","R&D spend fell to $103.8M from $187.6M, driven by program reprioritization and lower share-based compensation.","Pivotal epilepsy (opakalim) topline readout and Phase 2 obesity (taldefgrobep) data expected in 2H 2026.","Pivotal trials for BHV-1400 (IgAN) and BHV-1300 (Graves' disease) expected to initiate mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96802,"accession_number":"0001935979-26-000042","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biohaven shareholders elect three directors, ratify EY, approve say-on-pay at 2026 meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Michael T. Heffernan elected with 76.1M for, 15.1M against, 2.0M abstain; 32.1M broker non-votes.","Irina Antonijevic and Robert J. Hugin each elected with >76.5M votes for.","Ratification of Ernst & Young as FY2026 auditor passed with 123.7M for, 0.2M against.","Non-binding advisory vote on executive compensation approved with 87.5M for, 4.2M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111053,"accession_number":"0001935979-26-000022","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biohaven reports Q4 loss $145.6M, prioritizes three late-stage programs, raises $178.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $145.6M ($1.21/sh); non-GAAP adj. net loss $107.9M ($0.90/sh).","Cash, equivalents, securities $322M at year end; raised $178.9M via 17.2M share issuance.","Pivotal trial for IgAN degrader BHV-1400 starts Q1 2026; Graves' degrader BHV-1300 pivotal in 2H 2026.","Opakalim OLE: >50% seizure reduction in most on 75mg at 6 months; pivotal data due 2H 2026.","Taldefgrobep Phase 2 obesity initiated Q4 2025; topline results expected 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111052,"accession_number":"0001935979-26-000005","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biohaven files investor presentation; content unavailable in filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation furnished as Exhibit 99.1 on January 12, 2026.","No specific financial or operational data included in the provided text.","Investors should review the full presentation for material updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111051,"accession_number":"0001935979-26-000002","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Biohaven to issue 12.5M shares at $10 each to Janus Henderson, raising $125M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["12,500,000 common shares at $10.00 per share, $125M gross proceeds expected.","Buyer is Janus Henderson Investors; transaction is a block under existing ATM program.","Pricing at $10.00 per share; settlement pending fees and expenses.","Use of proceeds not specified in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127675,"accession_number":"0001628280-25-052066","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biohaven closes $200M public offering of 26.8M shares at $7.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of approximately $200M from 26,833,334 common shares, including full exercise of underwriters' 3.5M share option.","Offering price set at $7.50 per share; underwriters led by J.P. Morgan and Goldman Sachs.","Shares issued under shelf registration statement filed October 2, 2023 (File No. 333-274822).","Net proceeds after underwriting discounts and expenses not disclosed; expected for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127674,"accession_number":"0001935979-25-000090","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biohaven reports Q3 net loss $173.4M, plans 60% R&D spend cut to focus on three late-stage programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $173.4M ($1.64/share) vs $160.3M ($1.70/share) YoY; non-GAAP loss $155.9M ($1.47/share).","R&D spend $141.2M, down 10% YoY; plans ~60% reduction in direct R&D spend going forward.","Cash and equivalents $263.8M as of Sep 30, 2025.","Restructuring: focus on opakalim (Kv7), extracellular degraders (BHV-1400/1300), and taldefgrobep (myostatin); other programs paused/halted.","FDA Type A meeting requested to appeal CRL for SCA drug VYGLXIA; Phase 2 opakalim depression data expected Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144448,"accession_number":"0001935979-25-000080","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"FDA cancels advisory committee meeting for Biohaven's troriluzole NDA; decision still Q4 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA informed Biohaven on Aug 21, 2025 that an advisory committee meeting is no longer needed for troriluzole NDA review.","Previously, FDA had extended PDUFA by 3 months (to Q4 2025) and planned an AdComm.","Troriluzole is for treatment of adult Spinocerebellar Ataxia (SCA).","FDA's expected decision remains during Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144447,"accession_number":"0001935979-25-000074","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biohaven amends Knopp deal: royalty cut to mid-single digits, milestones reduced by >$800M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Removed up to $562.5M in commercial sales milestones; reduced developmental/regulatory milestones from $575M to up to $210M.","Replaced high-single-to-low-teens royalties with flat mid-single-digit royalty for BHV-7000 and pipeline.","Filed prospectus supplement for resale of 3,588,688 common shares issued as consideration for the Knopp Amendment.","Biohaven retains option to pay remaining contingent milestones in cash or shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144446,"accession_number":"0001935979-25-000067","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biohaven reports Q2 net loss $198M, cash $408.2M; OCD trial fails, VYGLXIA PDUFA in Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $198.1M ($1.94 per share) vs $319.8M in Q2 2024; no revenue, clinical-stage biopharma.","Cash, equivalents and marketable securities $408.2M as of June 30, 2025.","Phase 3 OCD trial with troriluzole showed no efficacy signal; program terminated.","VYGLXIA NDA for spinocerebellar ataxia under priority review, PDUFA in Q4 2025.","Early clinical data: BHV-1300 IgG reductions up to 87%, BHV-1510 ADC showed tumor reduction in first 6/6 patients with cemiplimab."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162812,"accession_number":"0001935979-25-000058","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biohaven files 8-K with investor presentation; content not disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed June 4, 2025 under Item 7.01 with investor presentation as Exhibit 99.1.","Presentation dated June 2025 but full content not available in this filing excerpt.","No specific financial or clinical data provided in the summary; further details unknown.","Ticker BHVN; NYSE listed; no material event specified in filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162811,"accession_number":"0001935979-25-000056","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA extends Biohaven's troriluzole PDUFA date to 4Q 2025, plans advisory committee meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA extends PDUFA date by 3 months to 4Q 2025 for troriluzole NDA for spinocerebellar ataxia (SCA).","FDA plans to hold an advisory committee meeting to discuss the application; no date set.","FDA did not raise new concerns; mid-cycle review found no major safety issues and no REMS needed.","Troriluzole has Fast-Track, Orphan Drug, and Priority Review status; would be first approved SCA treatment.","Clinical data showed 50-70% slowing of disease progression and reduced fall risk in SCA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162810,"accession_number":"0001935979-25-000053","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biohaven Q1 net loss $221.7M; announces $600M Oberland capital deal for troriluzole launch","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $221.7M ($2.17 per share); non-GAAP adjusted net loss $166.8M ($1.64 per share).","Cash as of April 30, 2025: ~$518M, after receiving $250M first tranche from Oberland Capital.","$600M non-dilutive note purchase with Oberland; includes regulatory milestone and royalty on troriluzole sales.","Troriluzole NDA for SCA under FDA priority review; PDUFA in Q3 2025; mid-cycle review completed without advisory committee.","Upcoming milestones: pivotal topline data for troriluzole in OCD in 1H 2025, BHV-7000 MDD data in 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162809,"accession_number":"0001935979-25-000049","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biohaven shareholders elect all director nominees and approve auditor ratification at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vlad Coric, M.D. re-elected with 61,631,560 votes for, 16,931,405 against; Kishan Mehta re-elected with 62,967,729 for, 15,578,703 against.","Ernst & Young LLP ratified as independent auditors for FY 2025 with 92,530,313 votes for, 100,413 against.","Non-binding advisory vote on named executive officer compensation approved with 67,470,380 for, 11,039,901 against.","Broker non-votes: 14,066,128 on director elections and compensation proposal; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162808,"accession_number":"0001935979-25-000026","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Biohaven secures up to $600M non-dilutive financing from Oberland Capital for troriluzole development","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["First tranche $250M funded at closing on or before April 30, 2025.","Second tranche up to $150M available upon FDA approval of troriluzole; third tranche up to $200M for acquisitions.","Oberland receives tiered single-digit royalties on global troriluzole net sales for up to 10 years, capped at multiples.","Additional milestone payment of 35% of funded amount upon FDA or EMA approval.","Proceeds to support ongoing clinical trials and commercialization preparations for troriluzole in SCA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180775,"accession_number":"0001935979-25-000016","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biohaven reports $489M cash; FDA accepts troriluzole NDA with Priority Review for SCA","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Cash & securities totaled $489M as of Dec 31, 2024; R&D expenses Q4 2024 were $167.5M (vs $134.8M Q4 2023).","FDA accepted troriluzole NDA for spinocerebellar ataxia with Priority Review; PDUFA date in 3Q 2025.","BHV-1300 (IgG degrader) achieved up to 84% reduction of total IgG in Phase 1; Phase 2 in Graves' disease expected mid-2025.","Next-gen TRAP degraders BHV-1400 (IgAN) and BHV-1600 (PPCM) advanced; Phase 1 completion expected 1H 2025.","Multiple pipeline milestones expected: BHV-7000 MDD topline 2H 2025, BHV-8000 Parkinson's study initiation 1H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180774,"accession_number":"0001935979-25-000008","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biohaven furnishes investor presentation for January 2025; full content not available.","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation attached as Exhibit 99.1, but the exhibit text is truncated or missing.","No specific financial or strategic figures can be extracted from the provided exhibit.","Investors should refer to the full presentation for material updates on pipeline or guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197611,"accession_number":"0001935979-24-000086","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biohaven reports Q3 net loss $160.3M; troriluzole SCA trial positive, NDA submission planned Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $160.3M ($1.70/sh) vs $102.6M loss ($1.50/sh) in Q3 2023; non-GAAP adj. net loss $164.1M ($1.74/sh).","Cash position $642M as of Oct 2, 2024, including $269.9M net from Oct 2024 public offering of 6.05M shares at $47.50.","Troriluzole met primary endpoint in pivotal SCA trial; NDA submission to FDA on track for Q4 2024.","Initiated Phase 2 trial of BHV-2100 (TRPM3 antagonist) in acute migraine; expects Phase 3 SMA topline data in Q4 2024.","R&D expenses rose to $157.6M from $95.5M YoY due to advancing late-stage trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197610,"accession_number":"0001628280-24-041894","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biohaven completes $287.5M equity offering; 6.05M shares at $47.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 6,052,631 common shares including full underwriter option at $47.50/share.","Gross proceeds ~$287.5M before underwriting discounts and expenses.","Underwriters were J.P. Morgan and Morgan Stanley; offering closed Oct. 2, 2024.","Prior to offering, Biohaven had 94,899,193 shares outstanding as of Sep. 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213847,"accession_number":"0001935979-24-000073","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Biohaven troriluzole pivotal SCA study meets primary endpoint; NDA planned Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Troriluzole 200 mg once-daily met primary endpoint on f-SARA change from baseline at 3 years in all SCA genotypes.","SCA patients showed 50-70% slower disease progression vs untreated controls, translating to 1.5-2.2 years delay.","Odds ratio for 2+ point f-SARA worsening at 3 years was 4.1 (95% CI: 2.1, 8.1; p<0.0001) favoring troriluzole.","Biohaven to submit NDA to FDA in Q4 2024; eligible for priority review given orphan/fast-track designations.","Company plans US commercialization in 2025 if approved; no FDA-approved treatments currently exist for SCA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213846,"accession_number":"0001628280-24-037576","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biohaven files prospectus for resale of 1.87M shares by selling shareholder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prospectus supplement filed for resale of 1,872,874 common shares issued to a selling shareholder as share consideration.","No new shares issued; shares were previously issued in connection with prior transactions and business arrangements.","Filing made under existing S-3 registration statement (No. 333-274822); legal opinion from Maples & Calder included as exhibit.","Selling shareholder named in the prospectus supplement will offer shares at prevailing market prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213845,"accession_number":"0001628280-24-037568","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biohaven expands at-the-market equity facility by $300M to total potential issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 1 increases existing ATM capacity by $300M in common shares; sales via J.P. Morgan as manager.","New shares offered under effective shelf registration (333-274822) with prospectus supplement filed August 16, 2024.","Sales depend on market conditions, share price, and capital needs; timing and amounts are at company's discretion.","Original Equity Distribution Agreement dated October 2, 2023; prior capacity not disclosed in this filing.","Proceeds from any sales will be used for general corporate purposes as determined by management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213844,"accession_number":"0001935979-24-000063","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biohaven Q2 net loss $3.64/sh; pipeline highlights MoDE degrader data and FDA alignment for BHV-8000","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $319.8M ($3.64/sh) in Q2 2024 vs $1.32/sh in Q2 2023; cash ~$440M.","R&D expense $314.8M includes $171.9M non-cash milestone/royalty buyback to Knopp for Kv7 platform.","MoDE platform: Phase 1 BHV-1300 showed dose-dependent IgG reduction, no SAEs; SC formulation had 44% higher exposure vs IV.","BHV-8000 (TYK2/JAK1) Phase 1 completed; FDA feedback enables registrational programs for Parkinson's and prevention of ARIA.","Taldefgrobep alfa: Phase 2 obesity trial and Phase 3 SMA topline data expected in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233067,"accession_number":"0001935979-24-000053","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biohaven files prospectus supplement for resale of 211,418 common shares by selling shareholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Prospectus supplement filed on May 17, 2024 for resale of 211,418 common shares issued as share consideration.","Shares were issued to selling shareholders in connection with prior transactions and business arrangements.","Legal opinion from Maples & Calder filed as Exhibit 5.1, incorporated into the S-3 registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233066,"accession_number":"0001935979-24-000047","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biohaven Q1 net loss $179.5M ($2.20/shr) vs $70.5M loss a year ago; cash $287.6M plus $247.8M from April offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $179.5M ($2.20/shr); non-GAAP adjusted net loss $144.6M ($1.77/shr); both more than doubled vs Q1 2023.","R&D expense $156.0M, up 146% YoY, driven by advancing trials and $16.6M in shares for Pyramid Biosciences acquisition.","Cash, equivalents and marketable securities $287.6M at March 31; additional $247.8M from April 2024 public offering of 6.45M shares at $41.","FDA granted rare pediatric disease designation for taldefgrobep alfa in SMA; Phase 3 data expected 2H 2024.","Phase 2/3 programs initiated with Kv7 activator BHV-7000 in epilepsy, MDD, and bipolar; BHV-1300 MoDE shows IgG reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233065,"accession_number":"0001935979-24-000035","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biohaven annual meeting: all three director nominees elected, auditor ratified, 1-year say-on-pay frequency approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Julia P. Gregory elected with 60,724,030 votes for, 412,143 against, 135,964 abstained.","John W. Childs elected with 60,799,707 votes for, 313,902 against, 158,528 abstained.","Gregory H. Bailey, M.D. elected with 46,277,398 votes for, 14,858,298 against, 136,441 abstained.","Ratification of Ernst & Young as independent auditor approved with 69,043,113 for, 154,493 against.","Say-on-pay frequency advisory vote: '1 Year' approved with 60,824,258 votes; board adopts annual frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233064,"accession_number":"0001628280-24-017139","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biohaven completes $264.5M public offering of common shares at $41.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued and sold 6,451,220 common shares at $41.00/share, including full exercise of underwriters' option.","Gross proceeds of approximately $264.5 million before underwriting discounts and offering expenses.","Underwriting agreement with J.P. Morgan Securities LLC as representative of several underwriters.","Offering made under effective shelf registration statement filed October 2, 2023 (File No. 333-274822)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233063,"accession_number":"0001935979-24-000031","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biohaven presents BHV-1300 Ph1 SAD data: safe, dose-dependent IgG lowering in 16 subjects","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["16 subjects completed two dosing cohorts; no SAEs, only mild AEs unrelated to drug.","Preliminary dose- and time-dependent IgG lowering observed; IgG1/2/4 reduction greater than IgG3.","BHV-1300 designed to spare IgG3; data consistent with preclinical nonhuman primate models.","Further program update planned at Company's R&D Day on May 29, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251218,"accession_number":"0001935979-24-000020","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biohaven registers 45,883 shares for resale by selling shareholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed prospectus supplement on Form S-3 for resale of 45,883 common shares.","Shares were issued as consideration in prior transactions and business arrangements.","No new shares issued; filing does not raise additional capital for Biohaven.","Legal opinion from Maples & Calder filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251217,"accession_number":"0001935979-24-000011","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biohaven reports Q4 net loss $144.8M, cash $385.5M; key pipeline data milestones in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net loss $144.8M ($1.81/sh); non-GAAP adj net loss $128.9M ($1.61/sh).","Cash, equivalents & securities $385.5M as of Dec 31, 2023 (incl. $3.7M restricted).","Public offering closed Oct 2023: 11.76M shares at $22, net proceeds ~$242.4M.","BHV-1300 Phase 1 IgG lowering data expected late Q1/early Q2 2024.","Troriluzole Phase 3 OCD interim analysis topline results expected Q2 2024; taldefgrobep SMA data H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251216,"accession_number":"0001935979-24-000002","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biohaven presents at J.P. Morgan Healthcare Conference; pipeline updates expected","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Vlad Coric presented at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024.","Presentation likely covers clinical trial progress for OCD and other pipeline programs.","No specific financial or clinical data disclosed in the exhibit text provided.","Form 8-K furnishes the presentation as Exhibit 99.1 under Regulation FD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268796,"accession_number":"0001935979-23-000064","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biohaven Q3 net loss $102.6M ($1.50/share); cash $495M after public offering; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $102.6M ($1.50/share) vs $68.9M ($1.75/share) in Q3 2022; non-GAAP adjusted net loss $98.1M ($1.44/share).","Cash, cash equivalents and securities $495M as of Oct 5, 2023, including $242M net from public offering of 11.76M shares at $22.","BHV-1300 IgG degrader showed >90% IgG reduction in non-human primates; IND submission on track for 2023.","BHV-7000 Phase 1 EEG study confirmed CNS target engagement; Phase 3 focal epilepsy trial to start in 2023.","Completed enrollment in Phase 3 study of taldefgrobep alfa in SMA; troriluzole MAA under EMA review."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268795,"accession_number":"0001628280-23-033962","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2023-10-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biohaven raises ~$258.7M in public offering of 11.8M shares at $22.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 11,761,363 common shares including full underwriter option at $22.00 per share.","Gross proceeds approximately $258.7 million before underwriting discounts and expenses.","Underwriting agreement with J.P. Morgan Securities LLC as representative of underwriters.","Offering made under effective shelf registration statement filed October 2, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268794,"accession_number":"0001628280-23-033545","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2023-10-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biohaven establishes $150M at-the-market equity offering program with J.P. Morgan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with J.P. Morgan Securities allows sale of up to $150M common shares via ATM program.","Sales may occur on NYSE at prevailing market prices or in negotiated transactions.","Company may sell shares periodically based on market conditions, capital needs, and other factors.","Registration statement on Form S-3 filed October 2, 2023 (File No. 333-274822).","Program provides added flexibility for potential future financing without immediate dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285903,"accession_number":"0001935979-23-000054","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2023-09-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biohaven reports >90% IgG reduction with BHV-1300 bispecific degrader after repeat dosing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BHV-1300 bispecific IgG degrader achieved >90% reduction in IgG after repeat dosing in pharmacodynamic study.","The data was disclosed in a new corporate presentation dated September 27, 2023.","BHV-1300 targets elimination of pathogenic IgG for autoimmune disease therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285902,"accession_number":"0001935979-23-000049","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biohaven Q2 net loss $90.3M; cash $349M; FDA refuses SCA3 NDA; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $90.3M ($1.32/sh) vs $203.3M ($5.16/sh) in Q2 2022; adjusted net loss $85.7M ($1.25/sh).","Cash and marketable securities $349.0M as of June 30, 2023, down from $467.9M at Dec 31, 2022.","BHV-7000 Kv7 activator showed CNS target engagement without somnolence; Phase 2/3 in epilepsy and bipolar disorder planned 2H 2023.","FDA refused to file troriluzole NDA for SCA3; Biohaven plans Type A meeting to address FDA concerns.","BHV-8000 (TYK2/JAK1) Phase 1 SAD dosed, well tolerated; Phase 2 in Parkinson's disease planned 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285901,"accession_number":"0001935979-23-000046","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2023-07-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA refuses troriluzole NDA for SCA; BHV-7000 EEG data positive","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA refused to file troriluzole NDA for SCA because primary endpoint not met; company may request Type A meeting within 30 days.","BHV-7000: preliminary EEG data shows target engagement with no somnolence/fatigue; pivotal studies in epilepsy/bipolar disorder planned for 2H2023.","BHV-8000 Phase 1: three dose cohorts dosed, well tolerated, achieved projected therapeutic concentrations; Phase 2 in Parkinson's planned for 2024.","BHV-1300 bispecific IgG degrader advancing to IND in 2H2023; competitive safety and manufacturing profile.","Once-daily extended-release formulation for BHV-7000 confirmed for Phase 2/3 programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305824,"accession_number":"0001935979-23-000037","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2023-05-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biohaven submits NDA for troriluzole in SCA3; updates on Kv7, TYK2/JAK1, and SMA pipeline","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted NDA to FDA for troriluzole in SCA3, an ultra-rare disease affecting ~10,600 people in NA, EU, Japan.","Phase 1 safety data for BHV-7000 (Kv7.2/3 activator) validates differentiated profile; pivotal studies in focal epilepsy and bipolar disorder planned in 2H2023.","Initiated Phase 1 study for BHV-8000 (brain-penetrant TYK2/JAK1 inhibitor); Phase 2 in Parkinson's expected next year.","Global Phase 3 trial of taldefgrobep alfa in SMA enrollment of ~225 patients expected to complete in 2023.","IND for novel IgG degrader BHV-1300 on track for submission in 2023; multiple new INDs planned within next year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305823,"accession_number":"0001935979-23-000033","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biohaven Q1 net loss $70.5M; cash $392M; pipeline progress, TYK2/JAK1 license acquired","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $70.5M ($1.03/share); non-GAAP adjusted net loss $66.7M ($0.98/share).","Cash and marketable securities $392.0M at March 31, 2023, down from $467.9M at Dec 31, 2022.","Acquired exclusive global rights (ex-China) to TYK2/JAK1 inhibitor BHV-8000; Phase 1 start planned in 2023.","Appointed Nick Kozauer (former FDA Division Director) as SVP of Clinical Development and Regulatory Strategy.","Anticipates H2 2023: Phase 2/3 for BHV-7000 in epilepsy/bipolar; IND submissions for BHV-7010, -2100, -1300."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305822,"accession_number":"0001935979-23-000019","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Biohaven amends option agreements for CEO, CFO, CSO; annual meeting results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended option agreements permit CEO Coric, CFO Buten, CSO Car to exercise options pre-vest in exchange for restricted shares.","Annual meeting turnout: 87.78% of 68,212,479 shares represented.","Directors elected: Heffernan (86.42%), Antonijevic (94.47%), Hugin (94.02%).","Ratification of Ernst & Young as auditor approved with 99.87% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325123,"accession_number":"0001935979-23-000016","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2023-03-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biohaven posts updated investor presentation for March 2023; details not in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Biohaven published an updated investor presentation on its website on March 23, 2023.","The presentation attached as Exhibit 99.1 shows only a cover page; no financial or pipeline details are included in the filing.","Investors should consult Biohaven's website directly for the full presentation content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325122,"accession_number":"0001935979-23-000014","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biohaven Q4 2022 net loss $201.1M; licenses TYK2/JAK1 inhibitor BHV-8000","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net loss $201.1M ($3.32/share); cash $465.3M at year-end, no debt.","Acquired exclusive global ex-China rights to oral brain-penetrant TYK2/JAK1 inhibitor BHV-8000; Phase 1 start planned in 2023.","Completed Phase 1 SAD/MAD for Kv7 activator BHV-7000; no sedation/dizziness/ataxia; plans EEG study H1 2023 and pivotal H2 2023.","Appointed Bruce Car (CSO), Irfan Qureshi (CMO), Tanya Fischer (CDO) to management team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325121,"accession_number":"0001935979-23-000003","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biohaven presents at J.P. Morgan conference; no specific data disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation made on January 10, 2023, at 41st Annual J.P. Morgan Healthcare Conference.","CEO Vlad Coric presented; no financial results, guidance, or pipeline updates in the exhibit.","No material changes or new disclosures identified in the 8-K or attached presentation.","Filing lacks substantive content beyond a title slide; investors should seek separate updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342898,"accession_number":"0001935979-22-000009","cik":1935979,"company_name":"Biohaven Ltd.","ticker":"BHVN","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biohaven posts Q3 net loss $68.9M; launches post-Pfizer with $257.8M cash, raises $301.9M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $68.9M ($1.75/share) vs $54.4M loss in Q3 2021; non-GAAP adjusted loss $49.2M ($1.25/share).","Cash at Sept 30: $50.7M; post-spin-off and $301.9M public offering, pro-forma cash ~$541M with no debt.","Spin-off from Pfizer completed Oct 3, 2022; BHVN began trading independently with $257.8M cash.","Closed public offering of 28.75M shares at $10.50/share, gross proceeds $301.9M (net $282.8M).","Pipeline milestones: BHV-7000 Phase 1 complete H1 2023; troriluzole Phase 3 OCD enrollment in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1582395992.7050488,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-09T23:59:59+00:00|342898"}